

Filed: August 26, 2016

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.

Petitioner,

v.

ASTRAZENECA AB

Patent Owner.

Case No. IPR2016-01316 (6,774,122)

Case No. IPR2016-01324 (7,456,160)

Case No. IPR2016-01325 (8,329,680)

Case No. IPR2016-01326 (8,466,139)¹

**SECOND UPDATED MANDATORY NOTICE PURSUANT TO
37 CFR §§ 42.8(a)(3) AND (b)(2)**

¹ A word-for-word identical Notice is being filed in each proceeding.

Pursuant to 37 C.F.R. §§ 42.8(a)(3) and 42.8(b)(2), Petitioner hereby identifies the following litigation in which United States Patent Nos. 6,774,122, 7,456,160, 8,329,680, and 8,466,139 are asserted by Patent Owner:

- *AstraZeneca Pharmaceuticals LP et al. v. Mylan Institutional LLC*,
Civil Action No. 1:16-cv-00669 (D. Del.), filed August 5, 2016.

Dated: August 26, 2016

/Brandon M. White/
Brandon M. White
Reg. No. 52,354
Perkins Coie LLP
700 13th St. NW, Suite 600
Washington, D.C. 20005
Telephone: (202) 654-6206
E-mail: bmwhite@perkinscoie.com

Attorney for Mylan Pharmaceuticals Inc.

CERTIFICATE OF SERVICE

The undersigned hereby certifies that the foregoing SECOND UPDATED MANDATORY NOTICE PURSUANT TO 37 CFR §§ 42.8(a)(3) AND (b)(2) was served electronically via email as follows:

Patent Owners:

Filko Prugo
O'Melveny & Myers LLP
fprugo@omm.com

Caitlin Hogan
O'Melveny & Myers LLP
chogan@omm.com

Marc Pensabene
O'Melveny & Myers LLP
mpensabene@omm.com

Kevin Murray
O'Melveny & Myers LLP
Kmurray2@omm.com

Dated: August 26, 2016

/Brandon M. White/
Brandon M. White

Attorney for Mylan Pharmaceuticals Inc.